
The treatment landscape of genitourinary malignancies has seen tremendous growth in the last decade with advancements in prostate, bladder, and urothelial cancers.

The treatment landscape of genitourinary malignancies has seen tremendous growth in the last decade with advancements in prostate, bladder, and urothelial cancers.

Leonard Gomella, MD, physician, professor, and chair of the Department of Urology at Thomas Jefferson University and Clinical Director Jefferson Sidney Kimmel Cancer Network, shares insight on genomic markers in patients with prostate cancer.

Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).

Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the future of biomarkers in prostate cancer that might complement or displace PSA.

Published: March 6th 2014 | Updated:

Published: May 13th 2016 | Updated:

Published: May 21st 2015 | Updated: